GDF11 and metabolic dysfunction-associated steatotic liver disease: Nine-day consecutive treatment with recombinant GDF11, injected IP at 1 mg/kg, in 16-18 months old wild type mice did not induce overt lipid accumulation or NAFLD, as quantified in micro steatosis or total fat accumulation (measured as % of the total imaged area) on H&E stained liver sections (Figure 3A, 3B) (n=5 per group).